Intraalveolar activation of the coagulation system due to reduced fibrinolytic function plays a critical role in the pathogenesis of interstitial lung disease. Recently, a new potent inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor, has been isolated and characterized from human plasma. This study evaluated the levels of thrombin-activatable fibrinolysis inhibitor and protein C inhibitor, another suppressor of fibrinolysis, in the bronchoalveolar lavage fluid from patients with interstitial lung disease. There were 82 patients with interstitial lung disease and 8 normal subjects. The bronchoalveolar lavage fluid levels of thrombin-activatable fibrinolysis inhibitor and protein C inhibitor were significantly higher in all patients with interstitial lung disease than in normal subjects. Both inhibitors of fibrinolysis were significantly and inversely correlated with fibrinolytic activity in all patients. The levels of thrombin-activatable fibrinolysis inhibitor were significantly correlated with those of protein C inhibitor, thrombin-antithrombin complex and monocyte chemoattractant protein-1. Reverse transcriptase-polymerase chain reaction showed that alveolar macrophages isolated from patients with interstitial lung disease as well as immortalized lung epithelial cell lines express thrombin-activatable fibrinolysis inhibitor antigen. Overall, these findings suggest that thrombin-activatable fibrinolysis inhibitor and protein C inhibitor may play important roles in the mechanism of intraalveolar hypofibrinolysis associated with interstitial lung diseases.
Introduction
Interstitial lung disease (ILD) is a group of disorders of the lower respiratory tract that results from injury of the lung parenchyma, increased proliferation of mesenchymal cells and excessive accumulation of connective-tissue matrix in the lung, causing ultimately lung fibrosis (1) . The exact mechanism of lung fibrosis is not clear but the results of studies carried out in experimental animal models suggested that decreased degradation of extracellular matrix due to deficient function of the alveolar fibrinolysis plays a fundamental role (2) . The primary enzyme of the fibrinolysis system is plasmin, a trypsin-like proteinase formed when the zymogen plasminogen is cleaved into its two-chain form by either tissue-type plasminogen activator or urokinase-type plasminogen activator. Plasmin can stimulate matrix degradation not only directly by degrading a number of extracellular matrix macromolecules but also indirectly by activating procollagenases and prostromelysins. Plasmin can also rapidly degrade fibrin formed after leakage of proteins and activation of coagulation cascade in the alveolar space (3, 4) . Under physiological conditions, the alveolar space has net fibrinolytic activity due to the presence of urokinase-type plasminogen activator (5, 6) . However, during many acute and chronic inflammatory lung disorders, fibrin accumulates in lung tissue (5, 7, 8) . The fibrinolytic activity in bronchoalveolar lavage fluid (BALF) from patients with the acute respiratory distress syndrome, idiopathic pulmonary fibrosis and sarcoidosis is reduced (8) (9) (10) . All of the above diseases have been associated with the development of pulmonary fibrosis. Depressed fibrinolysis has been also described in a variety of animal models of lung injury and fibrosis (11, 12) . The results of these experimental studies suggested that decreased plasmin activity mainly occurs due to overexpression of plasminogen activator inhibitor (PAI)-1, the primary inhibitor of both tissue and urokinase plasminogen activators (12) . It has been reported that bleomycin-induced lung fibrosis is more severe in transgenic mice which overexpressed PAI-1 than in PAI-1 deficient mice, and that bleomycin-treated PAI-1 deficient mice have enhanced fibrinolysis, less collagen build-up and longer survival than their PAI-1 expressing counterparts (13) . These observations suggest the biological significance of the fibrinolytic system dysfunction in the pathogenesis of ILD.
Recently, a new potent inhibitor of fibrinolysis, the thrombin-activatable fibrinolysis inhibitor (TAFI) or carboxypeptidase U, has been isolated and characterized from human plasma. TAFI is a (58 kDa) glycoprotein synthesized by the liver that can be activated by thrombin-, thrombin-thrombomodulin complex-, plasmin-or trypsin-catalyzed proteolysis to a carboxypeptidase B-like enzyme that inhibits fibrinolysis (14) . The thrombin-thrombomodulin complex-catalyzed activation of TAFI may be upregulated by protein C inhibitor (PCI); this serine protease inhibitor, also called plasminogen activator inhibitor-3, is the main suppressor of protein C activation and of the activity of activated protein C (15) (16) (17) . Activated protein C is a serine protease that stimulates fibrinolysis by binding to plasminogen activator-1 and by inhibiting thrombin generation (17). Thus, PCI may directly inhibit fibrinolysis by suppressing plasminogen activator and also indirectly by blocking the activity of activated protein C. It is well known that C-terminal lysines on cell-surface proteins and partially degraded fibrin enhance fibrinolysis by providing binding sites for plasminogen, which once bound, adopts a more activatable conformation. Activated TAFI (TAFIa) inhibits activation of plasminogen to plasmin by removing these C-terminal lysine residues (18). In addition, TAFIa may also directly inactivate plasmin further impairing fibrinolysis (19). The possibility that TAFI and PCI participate in the fibrinolytic system dysfunction in ILD patients is not known. The present study was undertaken to assess the levels of TAFI and PCI in the bronchoalveolar lavage fluid (BALF) in patients with ILD. Some of the results of this study have been previously reported in the form of an abstract (20).
Materials and Methods

Cell culture
The immortalized alveolar epithelial cell line, A549, was obtained from the American Type Culture Collection (Rockville, MD) the primary normal human bronchial epithelial (NHBE) cells were purchased from Clonetics (Walkersville, MD), and the human hepatic HepG2 cells from RIKEN Cell Bank (Ibaraki, Japan . For details see online data supplement.
Alveolar macrophage culture
BALF cells obtained from ILD patients were suspended in RPMI-1640 medium containing 2 mM glutamine, 10% FBS, 50 µg/ml penicillin and 50 µg/ml streptomycin, and then seeded in primary cell culture plates. The cells were allowed to adhere for 4 h in a humidified incubator (5% CO2, 95% air) at 37 ˚C. Non-adherent cells were removed by washing three times with RPMI-1640 medium and then the cells were used for total RNA preparation.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from cultured cells and tissues by the guanidine isothiocyanate procedure using Trizol Reagent (GIBCO, Grand Island, N.Y.). Two µg of total RNA were reverse transcribed using oligo-dT primers and then the cDNA was amplified by PCR using the Superscript Pre-amplification system kit (GIBCO Life Technologies) following the manufacturer's instructions. Primers and PCR conditions are described in online data supplement.
Patient population
This study comprised 82 newly diagnosed patients with ILD. There were 10 patients (male, 7; female, 3) with idiopathic pulmonary fibrosis (IPF), 34 (male, 15; female, 19) with sarcoidosis, 4 (male, 3; female, 1) with eosinophilic pneumonia (EP), 9 (male, 5; Data obtained in eight healthy volunteers served as controls.
Written informed consent was obtained from all subjects. The study protocol was approved by the Mie University Hospital Institutional Review Board and it was carried out following the principles of the Helsinki Declaration.
BALF sampling
BALF was obtained as previously described (22). A fiberoptic bronchoscope (Olympus 1T10, Olympus, Tokyo, Japan) was wedged into a segmental bronchus of the middle lobe or lingula. Four 50 ml aliquots of warmed sterile normal saline were instilled and retrieved immediately by suction at low negative pressure adjusted by a vacuum regulator. The pooled BAL was collected on ice and processed within 1 h.
The total amount of recovered fluid was measured and the recovery rate was calculated.
The BALF was filtered through two layers of sterile gauze and centrifuged at 150 g for 10 min at 4 ˚C. The cell-free supernatant was separated and stored in small aliquots at -80 ˚C until analysis. The cellular fraction was re-suspended in RPMI 1640 medium (Celox Laboratories, Minnesota, USA) and total cells were counted using a Neubauer haemocytometer counting chamber. Differential cell count was carried out in a Giemsa-stained cytocentrifuge preparation at X 1000 magnification.
Laboratory measurements
The BALF levels of PCI and thrombin-antithrombin complex (TAT) were measured by an enzyme immunoassay (EIA) using 96-well plate coated with anti-human PCI or TAT monoclonal antibody and, as second antibody, a biotin-labeled anti-human PCI or TAT monoclonal antibody. The inter-assay and intra-assay coefficients of variability were less than 10%. were measured using radioimmunoassay kits (Orion Diagnostica, Oulunsalo, Finland).
The intra-and inter-assay variations were less than 10%. The activity of plasminogen activator in BALF was spectrophotometrically measured using the chromogenic substrate S-2444 (Chromogenix, Molndal, Sweden). To measure the balance between coagulation activation and fibrinolytic activity, the ratio of plasminogen activator activity to TAT level in BALF from ILD patients was calculated. Protein concentration in BALF was measured by the Bradford's method using a protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Determination of fibrinolytic potential of PAI-1, PCI and TAFI in BALF was performed as described previously (23) (see method in online data supplement).
Statistical analysis
Data are expressed as the mean ± the standard error (SE) unless otherwise specified. 
Results
Concentrations of total protein, coagulation and collagen markers in BALF
The BALF concentration of total protein, an indicator of ongoing inflammation, was markedly elevated (P<0.05) in all patients with ILD (308.713 ± 27.582 µg/ml) as compared to the healthy control group (128.872 ± 36.538 µg/ml). This increase in (Table 1) .
Fibrinolytic activity in BALF
To evaluate whether biologically active TAFI is presence in BALF, the active form of TAFI was determined in BALF. The results disclosed that activated TAFI is significantly increased in BALF from all ILD patients compared to healthy controls (figure 4A). Experimental animals models have shown that lung injury is associated with suppressed fibrinolytic function. In the present study, we used the ratio of plasminogen activator activity to TAT level (PA activity/TAT) in BALF as an index of fibrinolytic function. The PA activity/TAT ratio in BALF was significantly higher in healthy controls than in all ILD patients (figure 4B), and particularly in patients with CVD-ILD, IPF and sarcoidosis (Table 2 ). These findings suggest that fibrinolytic function is impaired in ILD. The BALF levels of both TAFI and PCI were found to be inversely and significantly correlated with the PA activity/TAT ratio in all ILD patients (Table 1) . Analysis by group of disease showed that the PA activity/TAT ratio is significantly and inversely correlated with TAFI in BALF from patients with CVD-ILD, and with PCI and PAI-1 in BALF from patients with CVD-ILD and IPF. These results suggest that TAFI, PCI and PAI-1 are involved in the suppression of fibrinolysis in some groups of ILD patients. Analysis of the anti-fibrinolytic activity of each fibrinolysis inhibitor showed that PAI-1, PCI and TAFI have almost the same inhibitory potential in BALF of our ILD patients (figure 4E).
Circulating levels of TAFI and PCI and expression of TAFI in the lung
The plasma concentrations of TAFI and PCI were significantly higher in all ILD patients than in healthy controls (figure 4 C, D). Comparison between the mean values of the BALF and plasma levels of TAFI in all ILD patients showed that TAFI level is almost two-fold higher in BALF than in plasma (2495.3 ± 211 vs. 1279.8 ± 106).
It is known that the liver is the primary source of TAFI production (14) . In the present study, the expression of TAFI by alveolar macrophages isolated from patients with ILD, by an immortalized alveolar epithelial cell line (A549) and by a commercially purchased primary normal bronchial epithelial cells (NHBE) was evaluated by RT-PCR.
The results showed that A549 alveolar epithelial cell lines, primary normal bronchial epithelial cells and alveolar macrophages express TAFI mRNA (600 bp) (figure 5).
These findings suggest that TAFI may also increase in the intraalveolar space by direct TAFI release from lung cells.
Discussion
Plasmin, the effector enzyme of the fibrinolysis system impedes excessive accumulation of extracellular matrix in the lung by degrading it either directly or by activating the precursors of matrix metalloproteinases (4) . Decreased plasmin activity is believed to play a critical role in the augmented deposition of extracellular matrix in the ILD (5).
Up-regulation of PAI-1 during fibrotic processes is thought to be the explanation for the decreased plasmin activity, and subsequently, for the abnormal extracellular matrix deposition in ILD-associated lung fibrosis (figure 6) (13). In agreement with these findings, we found in the present study that reduced fibrinolytic activity, as estimated by the PA activity/TAT ratio, is associated with increased intraalveolar concentrations of PAI-1. Recent studies demonstrated that TAFI is also another potent inhibitor of plasmin generation (19). We found that the total intraalveolar level and the activity of TAFI are increased in patients with ILD. The level of TAFI was 6-to 7-fold higher than that detected in BALF from healthy subjects. These observations suggest that TAFI may also be an important causative factor of fibrinolytic impairment in ILD (figure 6). Increased concentration of procoagulant factors in the alveolar milieu may result from a spill-over of circulating plasma protein during lung inflammation. However, we found that alveolar macrophages isolated from ILD patients, primary bronchial epithelial cells and immortalized alveolar epithelial cell lines may themselves express TAFI, suggesting that local production of TAFI may also contribute to matrix deposition by further impairing the plasmin activity in the lung. The fact the concentration of TAFI was markedly higher in BALF than plasma of patients with ILD also suggests that TAFI antigen are locally produced and secreted from lung cells.
In brief, the results of this study showed for the first time that TAFI and PCI concentrations are increased in the intraalveolar space of patients with ILD and that, TAFI antigen may be locally produced by lung cells. These findings suggest that TAFI and PCI may play important roles in the mechanism of reduced plasmin activity in ILD.
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Materials and Methods
Reagents
Bovine serum albumin (BSA), Dulbecco's modified Eagle's medium (DMEM) and RPMI 1640 medium were from Sigma (St. Louis, MO). L-glutamine, vitamin solution, sodium pyruvate, non-essential amino acids, Trizol reagent and Superscript pre-amplification system™ were purchased from GIBCO (Grand Island, NY). Fetal bovine serum (FBS) was from Bio-Whittaker (Walkersville, MD) and penicillin, streptomycin and dexamethasone were from Nacalai Tesque (Kyoto, Japan). Anti-PA1
antibody was purchased from Technoclone (Vienna, Austria) and anti-PCI and anti-TAFI antibodies from Cerdalane Laboratories (Ontario, Canada). All other chemicals and reagents used were of the best quality commercially available.
Cell culture
The immortalized alveolar epithelial cell line, A549, was obtained from the American Type Culture Collection (Rockville, MD) the primary normal human bronchial epithelial (NHBE) cells were purchased from Clonetics (Walkersville, MD), and the human hepatic HepG2 cells from RIKEN Cell Bank (Ibaraki, Japan . A549 and HepG2 cells were cultured in DMEM containing 10% heat-inactivated FBS, 50 µg/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine, 2% vitamin solution, 110 µg/ml sodium pyruvate and 0.1 mM non-essential amino acids. NHBE cells were cultured in CCMD161 medium (Clonetics) supplemented with 30 µg/ml bovine pituitary extract, 1.5 ng/ml BSA, 0.5 µg/ml epinephrine, 50 µg/ml gentamycin, 50 ng/ml amphotericin B, 25 ng/ml human EGF, 0.5 µg/ml hydrocortisone, 5 µg/ml insulin, 7 ng/ml triiodothyronine, 10 µg/ml transferrin and 0.1 ng/ml retinoic acid. All cells were cultured in 10-cm dishes in an atmosphere composed of 5% CO 2 and 95% air.
Confluent cells were harvested by a brief exposure to 0.025% trypsin-0.02% EDTA and passaged after 5~7 days.
Alveolar macrophage culture
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from cultured cells and tissues by the guanidine isothiocyanate procedure using Trizol Reagent (GIBCO, Grand Island, N.Y.). Two µg of total RNA were reverse transcribed using oligo-dT primers and then the cDNA was amplified by PCR using the Superscript Pre-amplification system kit (GIBCO 
Statistical analysis
Data are expressed as the mean ± the standard error (SE) unless otherwise specified.
The statistical difference between two variables was calculated using the Wilcoxon's rank test. The strength of correlation between variables was calculated by the
